Lyell Immunopharma (NASDAQ:LYEL) Major Shareholder Venture Fund Xiii L.P. Arch Buys 2,321,262 Shares of Company Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) major shareholder Venture Fund Xiii L.P. Arch purchased 2,321,262 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The stock was bought at an average cost of $10.77 per share, for a total transaction of $24,999,991.74. Following the completion of the acquisition, the insider directly owned 3,747,790 shares in the company, valued at $40,363,698.30. The trade was a 162.72% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Lyell Immunopharma Stock Down 2.8%

LYEL traded down $0.43 during trading on Thursday, hitting $15.00. 657,433 shares of the company traded hands, compared to its average volume of 139,964. The firm has a market cap of $367.50 million, a P/E ratio of -1.17 and a beta of -0.04. The stock’s fifty day moving average is $10.85 and its 200 day moving average is $16.73. Lyell Immunopharma, Inc. has a one year low of $7.20 and a one year high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($1.86) EPS for the quarter, topping the consensus estimate of ($2.06) by $0.20. The business had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.01 million. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. On average, equities research analysts forecast that Lyell Immunopharma, Inc. will post -7.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on LYEL shares. Royal Bank Of Canada set a $34.00 price target on shares of Lyell Immunopharma in a report on Friday, August 14th. B. Riley Financial initiated coverage on Lyell Immunopharma in a report on Wednesday, July 22nd. They set a “buy” rating and a $44.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Thursday, October 15th. HC Wainwright reiterated a “buy” rating on shares of Lyell Immunopharma in a research note on Friday, September 11th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $44.00 price objective on shares of Lyell Immunopharma in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.86.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of LYEL. Allspring Global Investments Holdings LLC grew its position in shares of Lyell Immunopharma by 4.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 16,824 shares of the company’s stock valued at $158,000 after purchasing an additional 679 shares in the last quarter. Velan Capital Investment Management LP raised its position in shares of Lyell Immunopharma by 2.9% in the second quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company’s stock worth $1,475,000 after buying an additional 3,000 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of Lyell Immunopharma in the first quarter worth $445,000. Squarepoint Ops LLC boosted its stake in Lyell Immunopharma by 119.4% during the second quarter. Squarepoint Ops LLC now owns 42,322 shares of the company’s stock valued at $595,000 after buying an additional 23,028 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in Lyell Immunopharma during the second quarter valued at $347,000. 66.05% of the stock is owned by institutional investors.

More Lyell Immunopharma News

Here are the key news stories impacting Lyell Immunopharma this week:

• Positive Sentiment: Updated ronde-cel results showed high response rates in patients with relapsed or refractory large B-cell lymphoma: in the pivotal 3L+ trial, the overall response rate was 91% and the complete response rate was 77%; results in the 2L cohort were 95% and 76%, respectively. Severe cytokine release syndrome was not observed in either group. The data will be presented at the ASH meeting and support interest in the therapy’s potential. Article: Positive updated ronde-cel data
• Positive Sentiment: Lyell secured an approximately $80 million private placement to fund ronde-cel development toward a planned biologics license application (BLA). Needham also gave the shares a “Buy” rating, while a Seeking Alpha article cited the clinical progress and financing in an upgrade to “Buy.” Article: $80 million private placement Article: Needham Buy rating Article: Seeking Alpha upgrade
• Neutral Sentiment: Third-quarter loss per share was $1.86, narrower than analysts’ expected $2.06 loss, but revenue was zero. The earnings beat is modestly favorable, though the results underscore Lyell’s pre-commercial stage and ongoing losses. Article: Third-quarter results
• Negative Sentiment: The private placement involves selling common stock, which can dilute existing shareholders. Investors will also be weighing clinical promise against the remaining development and regulatory risks before ronde-cel can reach the market.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.